Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treat...
Saved in:
| Published in | The Lancet (British edition) Vol. 395; no. 10233; pp. 1345 - 1360 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
25.04.2020
Elsevier B.V Elsevier Limited Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0140-6736 1474-547X 1474-547X |
| DOI | 10.1016/S0140-6736(20)30552-3 |
Cover
| Abstract | Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance.
In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2–65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin–piperaquine or dihydroartemisinin–piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate–mefloquine or dihydroartemisinin–piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether–lumefantrine or artemether–lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete.
Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin–piperaquine (183 [17%]), dihydroartemisinin–piperaquine plus mefloquine (269 [24%]), artesunate–mefloquine (73 [7%]), artemether–lumefantrine (289 [26%]), or artemether–lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin–piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin–piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin–piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin–piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin–piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate–mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI −6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether–lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether–lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI −1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin–piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin–piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether–lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether–lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether–lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin–piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin–piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin–piperaquine plus mefloquine; p=0·50).
Dihydroartemisinin–piperaquine plus mefloquine and artemether–lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance.
UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health. |
|---|---|
| AbstractList | Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance.
In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2–65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin–piperaquine or dihydroartemisinin–piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate–mefloquine or dihydroartemisinin–piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether–lumefantrine or artemether–lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete.
Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin–piperaquine (183 [17%]), dihydroartemisinin–piperaquine plus mefloquine (269 [24%]), artesunate–mefloquine (73 [7%]), artemether–lumefantrine (289 [26%]), or artemether–lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin–piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin–piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin–piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin–piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin–piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate–mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI −6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether–lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether–lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI −1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin–piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin–piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether–lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether–lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether–lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin–piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin–piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin–piperaquine plus mefloquine; p=0·50).
Dihydroartemisinin–piperaquine plus mefloquine and artemether–lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance.
UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health. Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether-lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin-piperaquine plus mefloquine; p=0·50). Dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance. UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health. Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance.BACKGROUNDArtemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance.In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete.METHODSIn this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete.Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether-lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin-piperaquine plus mefloquine; p=0·50).FINDINGSBetween Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether-lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin-piperaquine plus mefloquine; p=0·50).Dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance.INTERPRETATIONDihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance.UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health.FUNDINGUK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health. Summary Background Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. Methods In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2–65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin–piperaquine or dihydroartemisinin–piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate–mefloquine or dihydroartemisinin–piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether–lumefantrine or artemether–lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. Findings Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin–piperaquine (183 [17%]), dihydroartemisinin–piperaquine plus mefloquine (269 [24%]), artesunate–mefloquine (73 [7%]), artemether–lumefantrine (289 [26%]), or artemether–lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin–piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin–piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin–piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin–piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin–piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate–mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI −6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether–lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether–lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI −1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin–piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin–piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether–lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether–lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether–lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin–piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin–piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin–piperaquine plus mefloquine; p=0·50). Interpretation Dihydroartemisinin–piperaquine plus mefloquine and artemether–lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance. Funding UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health. |
| Audience | Academic |
| Author | Gonçalves, Sónia Amaratunga, Chanaki Mayxay, Mayfong Hanboonkunupakarn, Borimas Grobusch, Martin P Woodrow, Charles J Lin, Khin Thuy-Nhien, Nguyen T Pyae Phyo, Aung Thuy-Nhien, Nguyen Thanh Valecha, Neena Valeche, Neena Jacob, Christopher G Mukaka, Mavuto Callery, James J Ghosh, Tarapada Newton, Paul N Tarning, Joel Hoglund, Richard M Day, Nicholas PJ Runcharern, Ratchadaporn van Vugt, Michele Onyamboko, Marie Jittamala, Podjanee Thant, Myo Waithira, Naomi ul Islam, Akhter Imwong, Mallika Lek, Dysoley Chotivanich, Kesinee Sreng, Sokunthea Hoa, Nhu Thi von Seidlein, Lorenz Yen, Sovannary Amato, Roberto Hien, Tran Tinh Sovann, Yok Mao, Sivanna Winterberg, Markus Huy, Rekol Satpathi, Parthasarathi Oun, Savuth Peto, Thomas J Tripura, Rupam Hlaing, Tin Maung Saelow, Chalermpon White, Nicholas J Chau, Nguyen Hoang Faiz, Abul Pearson, Richard D Mohanty, Akshaya Kumar Gantait, Kripasindhu Fairhurst, Rick M Thanh, Ngo Viet Heaton, James Fanello, Caterina Phyo, Aung Pyae Smithuis, Frank Satpathi, Sanghamitra Behera, Prativa Kumari Miotto, Olivo Anvikar, A |
| Author_xml | – sequence: 3 givenname: Richard M surname: Hoglund fullname: Hoglund, Richard M organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 4 givenname: Aung surname: Pyae Phyo fullname: Pyae Phyo, Aung organization: Myanmar-Oxford Clinical Research Unit, Yangon, Myanmar – sequence: 5 givenname: Dysoley surname: Lek fullname: Lek, Dysoley organization: National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia – sequence: 7 givenname: Anupkumar R surname: Anvikar fullname: Anvikar, Anupkumar R organization: National Institute of Malaria Research, Indian Council of Medical Research, New Delhi, India – sequence: 8 givenname: Parthasarathi surname: Satpathi fullname: Satpathi, Parthasarathi organization: Midnapore Medical College, Midnapur, India – sequence: 9 givenname: Sanghamitra surname: Satpathi fullname: Satpathi, Sanghamitra organization: Ispat General Hospital, Rourkela, India – sequence: 10 givenname: Prativa Kumari surname: Behera fullname: Behera, Prativa Kumari organization: Ispat General Hospital, Rourkela, India – sequence: 11 givenname: Amar surname: Tripura fullname: Tripura, Amar organization: Agartala Medical College, Tripura, India – sequence: 12 givenname: Subrata surname: Baidya fullname: Baidya, Subrata organization: Agartala Medical College, Tripura, India – sequence: 14 givenname: Nguyen Hoang surname: Chau fullname: Chau, Nguyen Hoang organization: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam – sequence: 15 givenname: Yok surname: Sovann fullname: Sovann, Yok organization: Pailin Provincial Health Department, Pailin, Cambodia – sequence: 18 givenname: Sivanna surname: Mao fullname: Mao, Sivanna organization: Sampov Meas Referral Hospital, Pursat, Cambodia – sequence: 19 givenname: Savuth surname: Oun fullname: Oun, Savuth organization: Ratanakiri Referral Hospital, Ratanakiri, Cambodia – sequence: 20 givenname: Sovannary surname: Yen fullname: Yen, Sovannary organization: Ratanakiri Referral Hospital, Ratanakiri, Cambodia – sequence: 21 givenname: Chanaki surname: Amaratunga fullname: Amaratunga, Chanaki organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 23 givenname: Chalermpon surname: Saelow fullname: Saelow, Chalermpon organization: Phu Sing hospital, Phu Sing, Sisaket, Thailand – sequence: 24 givenname: Ratchadaporn surname: Runcharern fullname: Runcharern, Ratchadaporn organization: Khun Han Hospital, Khun Han, Sisaket, Thailand – sequence: 25 givenname: Weerayuth surname: Kaewmok fullname: Kaewmok, Weerayuth organization: Khun Han Hospital, Khun Han, Sisaket, Thailand – sequence: 28 givenname: Borimas surname: Hanboonkunupakarn fullname: Hanboonkunupakarn, Borimas organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 30 givenname: Akshaya Kumar surname: Mohanty fullname: Mohanty, Akshaya Kumar organization: Infectious Disease Biology Unit, IGH, Rourkela Research Unit of ILS, Bhubeneswar, DBT, Rourkela, India – sequence: 31 givenname: James surname: Heaton fullname: Heaton, James organization: Myanmar-Oxford Clinical Research Unit, Yangon, Myanmar – sequence: 32 givenname: Myo surname: Thant fullname: Thant, Myo organization: Defence Services Medical Research Centre, Yangon, Myanmar – sequence: 33 givenname: Kripasindhu surname: Gantait fullname: Gantait, Kripasindhu organization: Midnapore Medical College, Midnapur, India – sequence: 34 givenname: Tarapada surname: Ghosh fullname: Ghosh, Tarapada organization: Midnapore Medical College, Midnapur, India – sequence: 35 givenname: Roberto surname: Amato fullname: Amato, Roberto organization: Nuffield Department of Medicine and MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK – sequence: 37 givenname: Christopher G surname: Jacob fullname: Jacob, Christopher G organization: Wellcome Sanger Institute, Hinxton, UK – sequence: 38 givenname: Sónia surname: Gonçalves fullname: Gonçalves, Sónia organization: Wellcome Sanger Institute, Hinxton, UK – sequence: 40 givenname: Naomi surname: Waithira fullname: Waithira, Naomi organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 42 givenname: Martin P surname: Grobusch fullname: Grobusch, Martin P organization: Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands – sequence: 43 givenname: Michele surname: van Vugt fullname: van Vugt, Michele organization: Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands – sequence: 44 givenname: Rick M surname: Fairhurst fullname: Fairhurst, Rick M organization: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA – sequence: 45 givenname: Phaik Yeong surname: Cheah fullname: Cheah, Phaik Yeong organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 48 givenname: Mehul surname: Dhorda fullname: Dhorda, Mehul organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 49 givenname: Richard J surname: Maude fullname: Maude, Richard J organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 50 givenname: Markus surname: Winterberg fullname: Winterberg, Markus organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 51 givenname: Nguyen Thanh surname: Thuy-Nhien fullname: Thuy-Nhien, Nguyen Thanh organization: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam – sequence: 52 givenname: Dominic P surname: Kwiatkowski fullname: Kwiatkowski, Dominic P organization: Nuffield Department of Medicine and MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK – sequence: 54 givenname: Podjanee surname: Jittamala fullname: Jittamala, Podjanee organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 55 givenname: Khin surname: Lin fullname: Lin, Khin organization: Department of Medical Research, Pyin Oo Lwin, Myanmar – sequence: 57 givenname: Kesinee surname: Chotivanich fullname: Chotivanich, Kesinee organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 58 givenname: Rekol surname: Huy fullname: Huy, Rekol organization: National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia – sequence: 60 givenname: Elizabeth surname: Ashley fullname: Ashley, Elizabeth organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 61 givenname: Mayfong surname: Mayxay fullname: Mayxay, Mayfong organization: Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Vientiane, Laos – sequence: 62 givenname: Paul N surname: Newton fullname: Newton, Paul N organization: Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK – sequence: 63 givenname: Tran Tinh surname: Hien fullname: Hien, Tran Tinh organization: Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK – sequence: 64 givenname: Neena surname: Valecha fullname: Valecha, Neena organization: National Institute of Malaria Research, Indian Council of Medical Research, New Delhi, India – sequence: 65 givenname: Frank surname: Smithuis fullname: Smithuis, Frank organization: Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK – sequence: 67 givenname: Abul surname: Faiz fullname: Faiz, Abul organization: Malaria Research Group and Dev Care Foundation, Dhaka, Bangladesh – sequence: 68 givenname: Olivo surname: Miotto fullname: Miotto, Olivo organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 69 givenname: Joel surname: Tarning fullname: Tarning, Joel organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 70 givenname: Nicholas P J surname: Day fullname: Day, Nicholas P J organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 71 givenname: Nicholas J surname: White fullname: White, Nicholas J organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 73 givenname: Rob W surname: van der Pluijm fullname: van der Pluijm, Rob W – sequence: 75 givenname: Richard M surname: Hoglund fullname: Hoglund, Richard M – sequence: 76 givenname: Aung Pyae surname: Phyo fullname: Phyo, Aung Pyae – sequence: 78 givenname: Akhter surname: ul Islam fullname: ul Islam, Akhter – sequence: 79 givenname: Anupkumar R surname: Anvikar fullname: Anvikar, Anupkumar R – sequence: 80 givenname: Parthasarathi surname: Satpathi fullname: Satpathi, Parthasarathi – sequence: 82 givenname: Prativa Kumari surname: Behera fullname: Behera, Prativa Kumari – sequence: 83 givenname: Amar surname: Tripura fullname: Tripura, Amar – sequence: 84 givenname: Subrata surname: Baidya fullname: Baidya, Subrata – sequence: 85 givenname: Marie surname: Onyamboko fullname: Onyamboko, Marie – sequence: 86 givenname: Nguyen Hoang surname: Chau fullname: Chau, Nguyen Hoang – sequence: 87 givenname: Yok surname: Sovann fullname: Sovann, Yok – sequence: 89 givenname: Sokunthea surname: Sreng fullname: Sreng, Sokunthea – sequence: 91 givenname: Savuth surname: Oun fullname: Oun, Savuth – sequence: 93 givenname: Chanaki surname: Amaratunga fullname: Amaratunga, Chanaki – sequence: 94 givenname: Kitipumi surname: Chutasmit fullname: Chutasmit, Kitipumi – sequence: 95 givenname: Chalermpon surname: Saelow fullname: Saelow, Chalermpon – sequence: 98 givenname: Nhu Thi surname: Hoa fullname: Hoa, Nhu Thi – sequence: 99 givenname: Ngo Viet surname: Thanh fullname: Thanh, Ngo Viet – sequence: 100 givenname: Borimas surname: Hanboonkunupakarn fullname: Hanboonkunupakarn, Borimas – sequence: 101 givenname: James J surname: Callery fullname: Callery, James J – sequence: 103 givenname: James surname: Heaton fullname: Heaton, James – sequence: 104 givenname: Myo surname: Thant fullname: Thant, Myo – sequence: 105 givenname: Kripasindhu surname: Gantait fullname: Gantait, Kripasindhu – sequence: 106 givenname: Tarapada surname: Ghosh fullname: Ghosh, Tarapada – sequence: 113 givenname: Charles J surname: Woodrow fullname: Woodrow, Charles J – sequence: 114 givenname: Martin P surname: Grobusch fullname: Grobusch, Martin P – sequence: 115 givenname: Michele surname: van Vugt fullname: van Vugt, Michele – sequence: 116 givenname: Rick M surname: Fairhurst fullname: Fairhurst, Rick M – sequence: 117 givenname: Phaik Yeong surname: Cheah fullname: Cheah, Phaik Yeong – sequence: 118 givenname: Thomas J surname: Peto fullname: Peto, Thomas J – sequence: 119 givenname: Lorenz surname: von Seidlein fullname: von Seidlein, Lorenz – sequence: 121 givenname: Richard J surname: Maude fullname: Maude, Richard J – sequence: 122 givenname: Markus surname: Winterberg fullname: Winterberg, Markus – sequence: 124 givenname: Dominic P surname: Kwiatkowski fullname: Kwiatkowski, Dominic P – sequence: 125 givenname: Mallika surname: Imwong fullname: Imwong, Mallika – sequence: 126 givenname: Podjanee surname: Jittamala fullname: Jittamala, Podjanee – sequence: 127 givenname: Khin surname: Lin fullname: Lin, Khin – sequence: 128 givenname: Tin Maung surname: Hlaing fullname: Hlaing, Tin Maung – sequence: 129 givenname: Kesinee surname: Chotivanich fullname: Chotivanich, Kesinee – sequence: 132 givenname: Elizabeth surname: Ashley fullname: Ashley, Elizabeth – sequence: 134 givenname: Paul N surname: Newton fullname: Newton, Paul N – sequence: 135 givenname: Tran Tinh surname: Hien fullname: Hien, Tran Tinh – sequence: 139 givenname: Abul surname: Faiz fullname: Faiz, Abul – sequence: 140 givenname: Olivo surname: Miotto fullname: Miotto, Olivo – sequence: 141 givenname: Joel surname: Tarning fullname: Tarning, Joel – sequence: 142 givenname: Nicholas PJ surname: Day fullname: Day, Nicholas PJ – sequence: 144 givenname: Arjen M surname: Dondorp fullname: Dondorp, Arjen M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32171078$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEUhgep2A_9CcqAIBU6mmQmya6iUopfUFCwgnfhbHKmTc0kY5JZ7O_zj5ndbYv2pr0IE8jzvuecOe9uteWDx6p6TMkLSqh4-Y3QjjRCtmKfkect4Zw17b1qh3aya3gnf2xVO9fIdrWb0jkhpBOEP6i2W0YlJXK2U_05iXZ0WEPMONhkvfXNAhKaWodhYT1kG3ydzzDCaDHVS4xpSnfG-xDryZe30VkNuXBfHaQhGDsNdQ9O2xFiuQ7gIFp4VUM9TC5bjT5HPKjDiL5xsEB3UEfwJpSiq2KuVNbg6lxE7mF1v1glfHT53au-f3h_cvSpOf7y8fPR4XGj-YzkxlA5M6ipYdD2dG6AGDKnQvCezRa65VqK3oAQwhCpu5npBNN0LoBKDsChb_eqtxvfcVoMaNY9glNjtAPECxXAqv9fvD1Tp2GpZox0TLJisH9pEMOvCVNWZRyNzoHHMCXFWilbXlbTFvTpDfQ8TNGX8RTrWEfLkV2hnm2oU3CobPnRPuPvfApTSkodirLmOed8BT75t_Xrnq-CUIDXG0DHkFLEXmmb19ssk1inKFGr2Kl17NQqU4oRtY6dWnXLb6ivCtyme7fRYVnb0mJUSVv0Go2NqLMywd7q8OaGw1U2fuLFHfR_ARa9CFI |
| CitedBy_id | crossref_primary_10_1016_j_jpha_2020_07_005 crossref_primary_10_1128_AAC_00990_21 crossref_primary_10_1186_s41182_024_00608_1 crossref_primary_10_1016_S1473_3099_21_00256_5 crossref_primary_10_51539_biotech_1149287 crossref_primary_10_1016_j_pt_2022_06_005 crossref_primary_10_1126_sciadv_adi2364 crossref_primary_10_4269_ajtmh_20_0852 crossref_primary_10_1093_trstmh_trad069 crossref_primary_10_1038_s41467_024_51846_0 crossref_primary_10_1016_S1473_3099_22_00492_3 crossref_primary_10_1080_14787210_2021_1962291 crossref_primary_10_1093_infdis_jiac232 crossref_primary_10_1186_s12936_020_03565_2 crossref_primary_10_1186_s12936_022_04382_5 crossref_primary_10_1056_NEJMe2110659 crossref_primary_10_1007_s00706_021_02759_x crossref_primary_10_1016_j_bmc_2021_116293 crossref_primary_10_1016_S0140_6736_23_01249_7 crossref_primary_10_1186_s12889_022_13212_x crossref_primary_10_4269_ajtmh_21_1268 crossref_primary_10_1186_s12936_020_03524_x crossref_primary_10_1038_s41598_023_41668_3 crossref_primary_10_1186_s41182_023_00572_2 crossref_primary_10_12688_wellcomeopenres_16065_1 crossref_primary_10_1016_j_freeradbiomed_2020_12_024 crossref_primary_10_1007_s13312_020_1888_5 crossref_primary_10_3389_fphar_2022_957690 crossref_primary_10_3390_ph14111109 crossref_primary_10_1128_cmr_00109_24 crossref_primary_10_1186_s12936_021_03858_0 crossref_primary_10_3390_jcm11030781 crossref_primary_10_3390_pharmaceutics14102047 crossref_primary_10_1371_journal_pone_0256567 crossref_primary_10_1016_j_ijantimicag_2024_107209 crossref_primary_10_1016_j_ijpddr_2021_09_005 crossref_primary_10_1186_s12936_024_04844_y crossref_primary_10_1360_TB_2022_0920 crossref_primary_10_1128_mbio_01832_23 crossref_primary_10_1128_AAC_02305_20 crossref_primary_10_1186_s12936_020_03197_6 crossref_primary_10_1128_AAC_00898_20 crossref_primary_10_1128_AAC_01639_20 crossref_primary_10_1016_j_drudis_2024_104254 crossref_primary_10_1186_s12936_023_04622_2 crossref_primary_10_1080_17460441_2023_2284820 crossref_primary_10_1002_wnan_1967 crossref_primary_10_1016_j_mib_2022_102193 crossref_primary_10_1146_annurev_micro_020518_115546 crossref_primary_10_5694_mja2_52398 crossref_primary_10_4269_ajtmh_22_0128 crossref_primary_10_22270_jddt_v15i3_7007 crossref_primary_10_1002_med_21848 crossref_primary_10_1186_s12879_022_07101_2 crossref_primary_10_3389_fcimb_2021_631545 crossref_primary_10_1016_j_chom_2021_11_002 crossref_primary_10_1016_j_chembiol_2024_02_008 crossref_primary_10_1016_j_heliyon_2024_e41086 crossref_primary_10_1016_S1473_3099_20_30929_4 crossref_primary_10_3390_ijms24054623 crossref_primary_10_1093_femsre_fuaa056 crossref_primary_10_3390_tropicalmed7120442 crossref_primary_10_1038_s41573_024_00933_4 crossref_primary_10_3390_ph14111129 crossref_primary_10_1055_a_1520_3764 crossref_primary_10_1016_j_biomaterials_2021_121100 crossref_primary_10_18632_aging_203874 crossref_primary_10_1080_08830185_2024_2336539 crossref_primary_10_1186_s12936_021_03649_7 crossref_primary_10_1038_s41579_024_01008_2 crossref_primary_10_1186_s12936_021_03762_7 crossref_primary_10_12688_wellcomeopenres_17736_3 crossref_primary_10_1371_journal_ppat_1011118 crossref_primary_10_1080_17425255_2022_2049235 crossref_primary_10_12688_wellcomeopenres_17736_4 crossref_primary_10_12688_wellcomeopenres_17736_1 crossref_primary_10_1093_jac_dkab181 crossref_primary_10_12688_wellcomeopenres_17736_2 crossref_primary_10_1128_AAC_01583_20 crossref_primary_10_1016_j_pt_2020_03_006 crossref_primary_10_1111_bph_15959 crossref_primary_10_1007_s10787_025_01682_5 crossref_primary_10_1016_j_pt_2020_07_004 crossref_primary_10_1016_j_pt_2020_09_011 crossref_primary_10_1371_journal_pone_0273249 crossref_primary_10_1016_j_bmc_2023_117339 crossref_primary_10_1016_j_pt_2023_09_011 crossref_primary_10_1016_j_parint_2020_102277 crossref_primary_10_1186_s12936_022_04079_9 crossref_primary_10_1016_j_jep_2023_117612 crossref_primary_10_1016_S0140_6736_20_32400_4 crossref_primary_10_1007_s10142_023_01028_w crossref_primary_10_1016_j_ejmech_2021_113193 crossref_primary_10_3390_microorganisms9020406 crossref_primary_10_1038_s41573_023_00772_9 crossref_primary_10_1038_s41467_022_30133_w crossref_primary_10_1038_s41591_023_02619_7 crossref_primary_10_1021_acsinfecdis_4c00418 crossref_primary_10_4269_ajtmh_22_0148 crossref_primary_10_1186_s12936_023_04763_4 crossref_primary_10_1186_s41182_023_00551_7 crossref_primary_10_3389_fcimb_2022_915656 crossref_primary_10_1016_j_diamond_2022_109670 crossref_primary_10_1016_j_pharmthera_2020_107688 crossref_primary_10_3390_jcm13226828 crossref_primary_10_1093_cid_ciaa625 crossref_primary_10_1016_j_ccr_2023_215633 crossref_primary_10_1016_S1473_3099_21_00748_9 crossref_primary_10_1080_22221751_2021_1888660 crossref_primary_10_1038_s41598_022_04985_7 crossref_primary_10_7554_eLife_77634 crossref_primary_10_1016_S1473_3099_24_00141_5 crossref_primary_10_1002_jmv_27616 crossref_primary_10_1016_j_lanmic_2024_100966 crossref_primary_10_3390_pharmaceutics16111416 crossref_primary_10_1084_jem_20211512 crossref_primary_10_1016_j_ejmech_2025_117292 crossref_primary_10_1016_j_trsl_2022_04_002 crossref_primary_10_1186_s12936_020_03436_w crossref_primary_10_1080_14786419_2024_2358524 crossref_primary_10_1093_infdis_jiab352 crossref_primary_10_1016_j_lpm_2022_104130 crossref_primary_10_1002_cmdc_202200414 crossref_primary_10_1080_07391102_2022_2077448 crossref_primary_10_1126_science_adp5137 crossref_primary_10_1016_j_chembiol_2023_04_006 crossref_primary_10_1038_s41467_024_54915_6 crossref_primary_10_1016_j_jddst_2020_102228 crossref_primary_10_1007_s00604_021_05126_z crossref_primary_10_1016_S1473_3099_21_00004_9 crossref_primary_10_3389_fphar_2023_1308400 crossref_primary_10_1038_s41467_023_39914_3 crossref_primary_10_1007_s40471_021_00266_5 crossref_primary_10_1016_S1473_3099_21_00692_7 crossref_primary_10_1128_AAC_01121_21 crossref_primary_10_1128_aac_01730_22 crossref_primary_10_1186_s12936_024_05233_1 crossref_primary_10_3390_ph14050412 crossref_primary_10_1080_07853890_2023_2221453 crossref_primary_10_1016_S0140_6736_20_32677_5 crossref_primary_10_1186_s12936_023_04666_4 crossref_primary_10_1084_jem_20210724 crossref_primary_10_1038_s41579_024_01099_x crossref_primary_10_1097_QCO_0000000000000766 crossref_primary_10_1093_jac_dkae300 crossref_primary_10_1080_14656566_2021_1959913 crossref_primary_10_1186_s12936_023_04532_3 crossref_primary_10_1186_s12936_022_04115_8 crossref_primary_10_1016_j_chembiol_2023_04_013 crossref_primary_10_3389_fphar_2022_876282 crossref_primary_10_1016_j_ebiom_2021_103384 crossref_primary_10_1111_bcp_14474 crossref_primary_10_1186_s12936_023_04481_x crossref_primary_10_1096_fj_202400004RR crossref_primary_10_1016_j_ebiom_2021_103377 crossref_primary_10_7554_eLife_72000 crossref_primary_10_1016_j_jchromb_2021_122887 crossref_primary_10_1016_j_jiac_2024_11_006 crossref_primary_10_1021_acs_jmedchem_1c00173 crossref_primary_10_1186_s13071_022_05239_1 crossref_primary_10_1371_journal_pone_0282099 crossref_primary_10_3390_pharmaceutics15071800 crossref_primary_10_1039_D1CS00343G crossref_primary_10_1093_ije_dyab259 crossref_primary_10_1016_j_ijpddr_2021_05_007 crossref_primary_10_1021_acsptsci_0c00110 crossref_primary_10_1186_s12936_022_04279_3 crossref_primary_10_1016_j_jbc_2021_100342 crossref_primary_10_1016_S0140_6736_20_30560_2 crossref_primary_10_1093_infdis_jiab055 crossref_primary_10_1186_s12916_021_02002_8 crossref_primary_10_3390_ph16020268 crossref_primary_10_1038_s41591_023_02551_w crossref_primary_10_1016_j_yexcr_2021_112678 crossref_primary_10_1002_cmdc_202200031 |
| Cites_doi | 10.1016/S1473-3099(15)00487-9 10.1186/s12936-019-2724-z 10.4269/ajtmh.14-0031 10.1093/cid/ciw388 10.1038/ncomms11553 10.1016/j.jchromb.2007.12.011 10.1016/S0140-6736(12)60484-X 10.1093/femsre/fuw037 10.1016/S1473-3099(17)30635-7 10.1128/AAC.00060-19 10.1038/nature00813 10.1186/s12916-018-1207-3 10.1016/j.tibtech.2012.12.006 10.1016/S0140-6736(96)01409-2 10.1016/S1473-3099(16)30409-1 10.1128/AAC.01793-10 10.1016/S1473-3099(17)30048-8 10.1016/S1473-3099(16)30415-7 10.1038/ng.3189 10.1128/AAC.02682-14 10.1093/cid/ciy1038 10.1186/1475-2875-10-339 10.1016/S1473-3099(19)30391-3 10.1038/s41467-018-04104-z 10.1016/j.jchromb.2008.10.018 10.1016/S1473-3099(19)30392-5 10.1126/science.1098876 10.1016/S1473-3099(18)30297-4 10.4269/ajtmh.2001.64.12 10.1128/AAC.01068-18 10.4155/bio.09.6 10.1056/NEJMoa1314981 |
| ContentType | Journal Article |
| Contributor | Gonçalves, Sónia Amaratunga, Chanaki Mayxay, Mayfong Ul Islam, Akhter Hanboonkunupakarn, Borimas Grobusch, Martin P Woodrow, Charles J Thuy-Nhien, Nguyen T Lin, Khin Valeche, Neena Jacob, Christopher G Mukaka, Mavuto Callery, James J Ghosh, Tarapada Newton, Paul N Tarning, Joel Hoglund, Richard M Runcharern, Ratchadaporn van Vugt, Michele Onyamboko, Marie Jittamala, Podjanee Thant, Myo Waithira, Naomi Imwong, Mallika Lek, Dysoley Chotivanich, Kesinee Sreng, Sokunthea Hoa, Nhu Thi von Seidlein, Lorenz Yen, Sovannary Amato, Roberto Hien, Tran Tinh Day, Nicholas Pj Sovann, Yok Mao, Sivanna Winterberg, Markus Huy, Rekol Satpathi, Parthasarathi Oun, Savuth Peto, Thomas J Tripura, Rupam Hlaing, Tin Maung Saelow, Chalermpon White, Nicholas J Chau, Nguyen Hoang Faiz, Abul Pearson, Richard D Mohanty, Akshaya Kumar Gantait, Kripasindhu Fairhurst, Rick M Thanh, Ngo Viet Heaton, James Fanello, Caterina Phyo, Aung Pyae Smithuis, Frank Satpathi, Sanghamitra Behera, Prativa Kumari Miotto, Olivo Anvikar, Anupkumar R Pukrittayakamee, Sasithon Suon, Seila Kaewmok |
| Contributor_xml | – sequence: 1 givenname: Rob W surname: van der Pluijm fullname: van der Pluijm, Rob W – sequence: 2 givenname: Rupam surname: Tripura fullname: Tripura, Rupam – sequence: 3 givenname: Richard M surname: Hoglund fullname: Hoglund, Richard M – sequence: 4 givenname: Aung Pyae surname: Phyo fullname: Phyo, Aung Pyae – sequence: 5 givenname: Dysoley surname: Lek fullname: Lek, Dysoley – sequence: 6 givenname: Akhter surname: Ul Islam fullname: Ul Islam, Akhter – sequence: 7 givenname: Anupkumar R surname: Anvikar fullname: Anvikar, Anupkumar R – sequence: 8 givenname: Parthasarathi surname: Satpathi fullname: Satpathi, Parthasarathi – sequence: 9 givenname: Sanghamitra surname: Satpathi fullname: Satpathi, Sanghamitra – sequence: 10 givenname: Prativa Kumari surname: Behera fullname: Behera, Prativa Kumari – sequence: 11 givenname: Amar surname: Tripura fullname: Tripura, Amar – sequence: 12 givenname: Subrata surname: Baidya fullname: Baidya, Subrata – sequence: 13 givenname: Marie surname: Onyamboko fullname: Onyamboko, Marie – sequence: 14 givenname: Nguyen Hoang surname: Chau fullname: Chau, Nguyen Hoang – sequence: 15 givenname: Yok surname: Sovann fullname: Sovann, Yok – sequence: 16 givenname: Seila surname: Suon fullname: Suon, Seila – sequence: 17 givenname: Sokunthea surname: Sreng fullname: Sreng, Sokunthea – sequence: 18 givenname: Sivanna surname: Mao fullname: Mao, Sivanna – sequence: 19 givenname: Savuth surname: Oun fullname: Oun, Savuth – sequence: 20 givenname: Sovannary surname: Yen fullname: Yen, Sovannary – sequence: 21 givenname: Chanaki surname: Amaratunga fullname: Amaratunga, Chanaki – sequence: 22 givenname: Kitipumi surname: Chutasmit fullname: Chutasmit, Kitipumi – sequence: 23 givenname: Chalermpon surname: Saelow fullname: Saelow, Chalermpon – sequence: 24 givenname: Ratchadaporn surname: Runcharern fullname: Runcharern, Ratchadaporn – sequence: 25 givenname: Weerayuth surname: Kaewmok fullname: Kaewmok, Weerayuth – sequence: 26 givenname: Nhu Thi surname: Hoa fullname: Hoa, Nhu Thi – sequence: 27 givenname: Ngo Viet surname: Thanh fullname: Thanh, Ngo Viet – sequence: 28 givenname: Borimas surname: Hanboonkunupakarn fullname: Hanboonkunupakarn, Borimas – sequence: 29 givenname: James J surname: Callery fullname: Callery, James J – sequence: 30 givenname: Akshaya Kumar surname: Mohanty fullname: Mohanty, Akshaya Kumar – sequence: 31 givenname: James surname: Heaton fullname: Heaton, James – sequence: 32 givenname: Myo surname: Thant fullname: Thant, Myo – sequence: 33 givenname: Kripasindhu surname: Gantait fullname: Gantait, Kripasindhu – sequence: 34 givenname: Tarapada surname: Ghosh fullname: Ghosh, Tarapada – sequence: 35 givenname: Roberto surname: Amato fullname: Amato, Roberto – sequence: 36 givenname: Richard D surname: Pearson fullname: Pearson, Richard D – sequence: 37 givenname: Christopher G surname: Jacob fullname: Jacob, Christopher G – sequence: 38 givenname: Sónia surname: Gonçalves fullname: Gonçalves, Sónia – sequence: 39 givenname: Mavuto surname: Mukaka fullname: Mukaka, Mavuto – sequence: 40 givenname: Naomi surname: Waithira fullname: Waithira, Naomi – sequence: 41 givenname: Charles J surname: Woodrow fullname: Woodrow, Charles J – sequence: 42 givenname: Martin P surname: Grobusch fullname: Grobusch, Martin P – sequence: 43 givenname: Michele surname: van Vugt fullname: van Vugt, Michele – sequence: 44 givenname: Rick M surname: Fairhurst fullname: Fairhurst, Rick M – sequence: 45 givenname: Phaik Yeong surname: Cheah fullname: Cheah, Phaik Yeong – sequence: 46 givenname: Thomas J surname: Peto fullname: Peto, Thomas J – sequence: 47 givenname: Lorenz surname: von Seidlein fullname: von Seidlein, Lorenz – sequence: 48 givenname: Mehul surname: Dhorda fullname: Dhorda, Mehul – sequence: 49 givenname: Richard J surname: Maude fullname: Maude, Richard J – sequence: 50 givenname: Markus surname: Winterberg fullname: Winterberg, Markus – sequence: 51 givenname: Nguyen T surname: Thuy-Nhien fullname: Thuy-Nhien, Nguyen T – sequence: 52 givenname: Dominic P surname: Kwiatkowski fullname: Kwiatkowski, Dominic P – sequence: 53 givenname: Mallika surname: Imwong fullname: Imwong, Mallika – sequence: 54 givenname: Podjanee surname: Jittamala fullname: Jittamala, Podjanee – sequence: 55 givenname: Khin surname: Lin fullname: Lin, Khin – sequence: 56 givenname: Tin Maung surname: Hlaing fullname: Hlaing, Tin Maung – sequence: 57 givenname: Kesinee surname: Chotivanich fullname: Chotivanich, Kesinee – sequence: 58 givenname: Rekol surname: Huy fullname: Huy, Rekol – sequence: 59 givenname: Caterina surname: Fanello fullname: Fanello, Caterina – sequence: 60 givenname: Elizabeth surname: Ashley fullname: Ashley, Elizabeth – sequence: 61 givenname: Mayfong surname: Mayxay fullname: Mayxay, Mayfong – sequence: 62 givenname: Paul N surname: Newton fullname: Newton, Paul N – sequence: 63 givenname: Tran Tinh surname: Hien fullname: Hien, Tran Tinh – sequence: 64 givenname: Neena surname: Valeche fullname: Valeche, Neena – sequence: 65 givenname: Frank surname: Smithuis fullname: Smithuis, Frank – sequence: 66 givenname: Sasithon surname: Pukrittayakamee fullname: Pukrittayakamee, Sasithon – sequence: 67 givenname: Abul surname: Faiz fullname: Faiz, Abul – sequence: 68 givenname: Olivo surname: Miotto fullname: Miotto, Olivo – sequence: 69 givenname: Joel surname: Tarning fullname: Tarning, Joel – sequence: 70 givenname: Nicholas Pj surname: Day fullname: Day, Nicholas Pj – sequence: 71 givenname: Nicholas J surname: White fullname: White, Nicholas J – sequence: 72 givenname: Arjen M surname: Dondorp fullname: Dondorp, Arjen M |
| Copyright | 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. COPYRIGHT 2020 Elsevier B.V. 2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2020 |
| Copyright_xml | – notice: 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license – notice: Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: COPYRIGHT 2020 Elsevier B.V. – notice: 2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2020 |
| CorporateAuthor | Tracking Resistance to Artemisinin Collaboration |
| CorporateAuthor_xml | – name: Tracking Resistance to Artemisinin Collaboration |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 5PM |
| DOI | 10.1016/S0140-6736(20)30552-3 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection ProQuest eLibrary (NC LIVE) ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences ProQuest Consumer Health Database (NC LIVE) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database ProQuest_Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1360 |
| ExternalDocumentID | PMC8204272 A621795554 32171078 10_1016_S0140_6736_20_30552_3 S0140673620305523 |
| Genre | Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Myanmar Cambodia Congo (Kinshasa) United Kingdom Thailand Laos India Bangladesh Vietnam Myanmar (Burma) Asia Africa |
| GeographicLocations_xml | – name: United Kingdom – name: Congo (Kinshasa) – name: India – name: Cambodia – name: Myanmar – name: Laos – name: Thailand – name: Asia – name: Vietnam – name: Myanmar (Burma) – name: Bangladesh – name: Africa |
| GrantInformation | UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health. |
| GrantInformation_xml | – fundername: Wellcome Trust grantid: 201900 – fundername: Wellcome Trust grantid: 206194 – fundername: Wellcome Trust grantid: 090770 – fundername: Medical Research Council grantid: MR/M006212/1 – fundername: Wellcome Trust grantid: 204911/Z/16/Z – fundername: Wellcome Trust grantid: 106698/B/14/Z |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT 04C 6I. 88A AACTN AAFTH ABLVK ABYKQ AFKWA AJOXV AMFUW M0L SDF XFK ZA5 .GJ 3EH 3O- 41~ 8WZ A6W AAEJM AAKAS AAQQT AAQXK AAYOK AAYXX ABDBF ABWVN ACRPL ACUHS ADMUD ADNMO ADXHL ADZCM AFCTW AFFNX AGQPQ AGRNS AHHHB AHQJS AIGII AJJEV AKVCP ALIPV ARTTT ASPBG AVWKF AZFZN CITATION D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H MVM OVD Q~Q R2- RIG SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 ACLOT ~HD 5PM |
| ID | FETCH-LOGICAL-c580t-d178dec1d2a3f19da0d091665f28bc35c76fda666d07c48d462c196a175aa5af3 |
| IEDL.DBID | 7X7 |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Thu Aug 21 13:52:37 EDT 2025 Sun Sep 28 04:04:58 EDT 2025 Sat Aug 16 17:52:54 EDT 2025 Fri Jun 27 05:46:06 EDT 2025 Mon Jul 21 06:05:15 EDT 2025 Tue Jul 01 04:23:36 EDT 2025 Thu Apr 24 22:54:31 EDT 2025 Fri Feb 23 02:47:08 EST 2024 Tue Aug 26 17:12:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10233 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c580t-d178dec1d2a3f19da0d091665f28bc35c76fda666d07c48d462c196a175aa5af3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8204272 |
| PMID | 32171078 |
| PQID | 2424142474 |
| PQPubID | 40246 |
| PageCount | 16 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8204272 proquest_miscellaneous_2377351713 proquest_journals_2424142474 gale_incontextgauss__A621795554 pubmed_primary_32171078 crossref_citationtrail_10_1016_S0140_6736_20_30552_3 crossref_primary_10_1016_S0140_6736_20_30552_3 elsevier_sciencedirect_doi_10_1016_S0140_6736_20_30552_3 elsevier_clinicalkey_doi_10_1016_S0140_6736_20_30552_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-25 |
| PublicationDateYYYYMMDD | 2020-04-25 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2020 |
| Publisher | Elsevier Ltd Elsevier B.V Elsevier Limited Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier B.V – name: Elsevier Limited – name: Elsevier |
| References | Hanpithakpong, Kamanikom, Dondorp (bib23) 2008; 876 Ashley, Dhorda, Fairhurst (bib2) 2014; 371 Onyamboko, Fanello, Wongsaen (bib34) 2014; 58 Amato, Lim, Miotto (bib14) 2017; 17 Bopp, Magistrado, Wong (bib16) 2018; 9 Phyo, Nkhoma, Stepniewska (bib25) 2012; 379 Hamilton, Amato, van der Pluijm (bib26) 2019; 19 Flegg, Guerin, White, Stepniewska (bib21) 2011; 10 (bib19) April, 2015 (bib27) 2019; 17 Miotto, Amato, Ashley (bib36) 2015; 47 Lindegardh, Annerberg, White, Day (bib22) 2008; 862 Roper, Pearce, Nair, Sharp, Nosten, Anderson (bib9) 2004; 305 Hanboonkunupakarn, van der Pluijm, Hoglund (bib33) 2019; 63 bib28 Woodrow, White (bib3) 2017; 41 Tse, Korsik, Todd (bib7) 2019; 18 Phyo, Ashley, Anderson (bib4) 2016; 63 Dini, Zaloumis, Cao (bib12) 2018; 62 Imwong, Suwannasin, Kunasol (bib6) 2017; 17 Amaratunga, Lim, Suon (bib13) 2016; 16 Wootton, Feng, Ferdig (bib8) 2002; 418 Trape (bib10) 2001; 64 bib20 Hanpithakpong, Kamanikom, Singhasivanon, White, Day, Lindegardh (bib24) 2009; 1 Nguyen, Day, Ly (bib29) 1996; 348 van der Pluijm, Imwong, Chau (bib5) 2019; 19 Das, Manna, Saha, Hati, Roy (bib35) 2019; 69 Rossi, De Smet, Khim, Kindermans, Menard (bib32) 2017; 17 bib1 Veiga, Dhingra, Henrich (bib18) 2016; 7 Witkowski, Duru, Khim (bib31) 2017; 17 Worthington, Melander (bib11) 2013; 31 Eastman, Dharia, Winzeler, Fidock (bib15) 2011; 55 Venkatesan, Gadalla, Stepniewska (bib17) 2014; 91 Chan, Win, Mawer, Tan, Brugada, White (bib30) 2018; 18 Worthington (10.1016/S0140-6736(20)30552-3_bib11) 2013; 31 Das (10.1016/S0140-6736(20)30552-3_bib35) 2019; 69 Tse (10.1016/S0140-6736(20)30552-3_bib7) 2019; 18 (10.1016/S0140-6736(20)30552-3_bib19) 2015 (10.1016/S0140-6736(20)30552-3_bib27) 2019; 17 Ashley (10.1016/S0140-6736(20)30552-3_bib2) 2014; 371 Woodrow (10.1016/S0140-6736(20)30552-3_bib3) 2017; 41 Phyo (10.1016/S0140-6736(20)30552-3_bib25) 2012; 379 Amaratunga (10.1016/S0140-6736(20)30552-3_bib13) 2016; 16 Nguyen (10.1016/S0140-6736(20)30552-3_bib29) 1996; 348 Venkatesan (10.1016/S0140-6736(20)30552-3_bib17) 2014; 91 Miotto (10.1016/S0140-6736(20)30552-3_bib36) 2015; 47 Amato (10.1016/S0140-6736(20)30552-3_bib14) 2017; 17 Lindegardh (10.1016/S0140-6736(20)30552-3_bib22) 2008; 862 Rossi (10.1016/S0140-6736(20)30552-3_bib32) 2017; 17 Hanboonkunupakarn (10.1016/S0140-6736(20)30552-3_bib33) 2019; 63 Wootton (10.1016/S0140-6736(20)30552-3_bib8) 2002; 418 Bopp (10.1016/S0140-6736(20)30552-3_bib16) 2018; 9 Hamilton (10.1016/S0140-6736(20)30552-3_bib26) 2019; 19 Hanpithakpong (10.1016/S0140-6736(20)30552-3_bib24) 2009; 1 Roper (10.1016/S0140-6736(20)30552-3_bib9) 2004; 305 Dini (10.1016/S0140-6736(20)30552-3_bib12) 2018; 62 Flegg (10.1016/S0140-6736(20)30552-3_bib21) 2011; 10 Phyo (10.1016/S0140-6736(20)30552-3_bib4) 2016; 63 van der Pluijm (10.1016/S0140-6736(20)30552-3_bib5) 2019; 19 Chan (10.1016/S0140-6736(20)30552-3_bib30) 2018; 18 Hanpithakpong (10.1016/S0140-6736(20)30552-3_bib23) 2008; 876 Imwong (10.1016/S0140-6736(20)30552-3_bib6) 2017; 17 Eastman (10.1016/S0140-6736(20)30552-3_bib15) 2011; 55 Trape (10.1016/S0140-6736(20)30552-3_bib10) 2001; 64 Onyamboko (10.1016/S0140-6736(20)30552-3_bib34) 2014; 58 Veiga (10.1016/S0140-6736(20)30552-3_bib18) 2016; 7 Witkowski (10.1016/S0140-6736(20)30552-3_bib31) 2017; 17 32240626 - Lancet. 2020 Apr 25;395(10233):1344. doi: 10.1016/S0140-6736(20)30738-8. 33341138 - Lancet. 2021 Dec 19;396(10267):1976. doi: 10.1016/S0140-6736(20)32400-4. 32171077 - Lancet. 2020 Apr 25;395(10233):1316-1317. doi: 10.1016/S0140-6736(20)30560-2. |
| References_xml | – volume: 7 start-page: 11553 year: 2016 ident: bib18 article-title: Globally prevalent PfMDR1 mutations modulate publication-title: Nat Commun – volume: 305 start-page: 1124 year: 2004 ident: bib9 article-title: Intercontinental spread of pyrimethamine-resistant malaria publication-title: Science – volume: 47 start-page: 226 year: 2015 end-page: 234 ident: bib36 article-title: Genetic architecture of artemisinin-resistant publication-title: Nat Genet – volume: 69 start-page: 1144 year: 2019 end-page: 1152 ident: bib35 article-title: Novel pfkelch13 gene polymorphism associates with artemisinin resistance in eastern India publication-title: Clin Infect Dis – volume: 55 start-page: 3908 year: 2011 end-page: 3916 ident: bib15 article-title: Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured publication-title: Antimicrob Agents Chemother – volume: 63 start-page: e00060 year: 2019 end-page: e00119 ident: bib33 article-title: Sequential open-label study of the safety, tolerability, and pharmacokinetic interactions between dihydroartemisinin-piperaquine and mefloquine in healthy Thai adults publication-title: Antimicrob Agents Chemother – volume: 9 start-page: 1769 year: 2018 ident: bib16 article-title: Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian publication-title: Nat Commun – volume: 64 start-page: 12 year: 2001 end-page: 17 ident: bib10 article-title: The public health impact of chloroquine resistance in Africa publication-title: Am J Trop Med Hyg – volume: 379 start-page: 1960 year: 2012 end-page: 1966 ident: bib25 article-title: Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study publication-title: Lancet – ident: bib20 article-title: Version 2.0. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services. November, 2014 – volume: 876 start-page: 61 year: 2008 end-page: 68 ident: bib23 article-title: A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 10 start-page: 339 year: 2011 ident: bib21 article-title: Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator publication-title: Malar J – ident: bib28 article-title: Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization, 2008 – volume: 371 start-page: 411 year: 2014 end-page: 423 ident: bib2 article-title: Spread of artemisinin resistance in publication-title: N Engl J Med – volume: 91 start-page: 833 year: 2014 end-page: 843 ident: bib17 article-title: Polymorphisms in publication-title: Am J Trop Med Hyg – year: April, 2015 ident: bib19 publication-title: Guidelines for the treatment of malaria, 3rd edn. – ident: bib1 article-title: World malaria report 2019. Geneva: World Health Organization, 2019 – volume: 17 start-page: 174 year: 2017 end-page: 183 ident: bib31 article-title: A surrogate marker of piperaquine-resistant publication-title: Lancet Infect Dis – volume: 18 start-page: 913 year: 2018 end-page: 923 ident: bib30 article-title: Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis publication-title: Lancet Infect Dis – volume: 19 start-page: 943 year: 2019 end-page: 951 ident: bib26 article-title: Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study publication-title: Lancet Infect Dis – volume: 18 start-page: 93 year: 2019 ident: bib7 article-title: The past, present and future of anti-malarial medicines publication-title: Malar J – volume: 348 start-page: 917 year: 1996 end-page: 921 ident: bib29 article-title: Post-malaria neurological syndrome publication-title: Lancet – volume: 19 start-page: 952 year: 2019 end-page: 961 ident: bib5 article-title: Determinants of dihydroartemisinin-piperaquine treatment failure in publication-title: Lancet Infect Dis – volume: 17 start-page: 491 year: 2017 end-page: 497 ident: bib6 article-title: The spread of artemisinin-resistant publication-title: Lancet Infect Dis – volume: 17 start-page: 164 year: 2017 end-page: 173 ident: bib14 article-title: Genetic markers associated with dihydroartemisinin-piperaquine failure in publication-title: Lancet Infect Dis – volume: 17 start-page: 1 year: 2019 ident: bib27 article-title: Association of mutations in the publication-title: BMC Med – volume: 862 start-page: 227 year: 2008 end-page: 236 ident: bib22 article-title: Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 1 start-page: 37 year: 2009 end-page: 46 ident: bib24 article-title: A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma publication-title: Bioanalysis – volume: 41 start-page: 34 year: 2017 end-page: 48 ident: bib3 article-title: The clinical impact of artemisinin resistance in southeast Asia and the potential for future spread publication-title: FEMS Microbiol Rev – volume: 62 start-page: e01068 year: 2018 end-page: e01118 ident: bib12 article-title: Investigating the efficacy of triple artemisinin-based combination therapies for treating publication-title: Antimicrob Agents Chemother – volume: 58 start-page: 5528 year: 2014 end-page: 5536 ident: bib34 article-title: Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute publication-title: Antimicrob Agents Chemother – volume: 418 start-page: 320 year: 2002 end-page: 323 ident: bib8 article-title: Genetic diversity and chloroquine selective sweeps in publication-title: Nature – volume: 31 start-page: 177 year: 2013 end-page: 184 ident: bib11 article-title: Combination approaches to combat multidrug-resistant bacteria publication-title: Trends Biotechnol – volume: 63 start-page: 784 year: 2016 end-page: 791 ident: bib4 article-title: Declining efficacy of artemisinin combination therapy against publication-title: Clin Infect Dis – volume: 16 start-page: 357 year: 2016 end-page: 365 ident: bib13 article-title: Dihydroartemisinin-piperaquine resistance in publication-title: Lancet Infect Dis – volume: 17 start-page: 1233 year: 2017 ident: bib32 article-title: Emergence of publication-title: Lancet Infect Dis – volume: 16 start-page: 357 year: 2016 ident: 10.1016/S0140-6736(20)30552-3_bib13 article-title: Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00487-9 – volume: 18 start-page: 93 year: 2019 ident: 10.1016/S0140-6736(20)30552-3_bib7 article-title: The past, present and future of anti-malarial medicines publication-title: Malar J doi: 10.1186/s12936-019-2724-z – volume: 91 start-page: 833 year: 2014 ident: 10.1016/S0140-6736(20)30552-3_bib17 article-title: Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.14-0031 – volume: 63 start-page: 784 year: 2016 ident: 10.1016/S0140-6736(20)30552-3_bib4 article-title: Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors publication-title: Clin Infect Dis doi: 10.1093/cid/ciw388 – volume: 7 start-page: 11553 year: 2016 ident: 10.1016/S0140-6736(20)30552-3_bib18 article-title: Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies publication-title: Nat Commun doi: 10.1038/ncomms11553 – year: 2015 ident: 10.1016/S0140-6736(20)30552-3_bib19 – volume: 862 start-page: 227 year: 2008 ident: 10.1016/S0140-6736(20)30552-3_bib22 article-title: Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2007.12.011 – volume: 379 start-page: 1960 year: 2012 ident: 10.1016/S0140-6736(20)30552-3_bib25 article-title: Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study publication-title: Lancet doi: 10.1016/S0140-6736(12)60484-X – volume: 41 start-page: 34 year: 2017 ident: 10.1016/S0140-6736(20)30552-3_bib3 article-title: The clinical impact of artemisinin resistance in southeast Asia and the potential for future spread publication-title: FEMS Microbiol Rev doi: 10.1093/femsre/fuw037 – volume: 17 start-page: 1233 year: 2017 ident: 10.1016/S0140-6736(20)30552-3_bib32 article-title: Emergence of Plasmodium falciparum triple mutant in Cambodia publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30635-7 – volume: 63 start-page: e00060 year: 2019 ident: 10.1016/S0140-6736(20)30552-3_bib33 article-title: Sequential open-label study of the safety, tolerability, and pharmacokinetic interactions between dihydroartemisinin-piperaquine and mefloquine in healthy Thai adults publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00060-19 – volume: 418 start-page: 320 year: 2002 ident: 10.1016/S0140-6736(20)30552-3_bib8 article-title: Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum publication-title: Nature doi: 10.1038/nature00813 – volume: 17 start-page: 1 year: 2019 ident: 10.1016/S0140-6736(20)30552-3_bib27 article-title: Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis publication-title: BMC Med doi: 10.1186/s12916-018-1207-3 – volume: 31 start-page: 177 year: 2013 ident: 10.1016/S0140-6736(20)30552-3_bib11 article-title: Combination approaches to combat multidrug-resistant bacteria publication-title: Trends Biotechnol doi: 10.1016/j.tibtech.2012.12.006 – volume: 348 start-page: 917 year: 1996 ident: 10.1016/S0140-6736(20)30552-3_bib29 article-title: Post-malaria neurological syndrome publication-title: Lancet doi: 10.1016/S0140-6736(96)01409-2 – volume: 17 start-page: 164 year: 2017 ident: 10.1016/S0140-6736(20)30552-3_bib14 article-title: Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(16)30409-1 – volume: 55 start-page: 3908 year: 2011 ident: 10.1016/S0140-6736(20)30552-3_bib15 article-title: Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01793-10 – volume: 17 start-page: 491 year: 2017 ident: 10.1016/S0140-6736(20)30552-3_bib6 article-title: The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30048-8 – volume: 17 start-page: 174 year: 2017 ident: 10.1016/S0140-6736(20)30552-3_bib31 article-title: A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(16)30415-7 – volume: 47 start-page: 226 year: 2015 ident: 10.1016/S0140-6736(20)30552-3_bib36 article-title: Genetic architecture of artemisinin-resistant Plasmodium falciparum publication-title: Nat Genet doi: 10.1038/ng.3189 – volume: 58 start-page: 5528 year: 2014 ident: 10.1016/S0140-6736(20)30552-3_bib34 article-title: Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02682-14 – volume: 69 start-page: 1144 year: 2019 ident: 10.1016/S0140-6736(20)30552-3_bib35 article-title: Novel pfkelch13 gene polymorphism associates with artemisinin resistance in eastern India publication-title: Clin Infect Dis doi: 10.1093/cid/ciy1038 – volume: 10 start-page: 339 year: 2011 ident: 10.1016/S0140-6736(20)30552-3_bib21 article-title: Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator publication-title: Malar J doi: 10.1186/1475-2875-10-339 – volume: 19 start-page: 952 year: 2019 ident: 10.1016/S0140-6736(20)30552-3_bib5 article-title: Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(19)30391-3 – volume: 9 start-page: 1769 year: 2018 ident: 10.1016/S0140-6736(20)30552-3_bib16 article-title: Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum publication-title: Nat Commun doi: 10.1038/s41467-018-04104-z – volume: 876 start-page: 61 year: 2008 ident: 10.1016/S0140-6736(20)30552-3_bib23 article-title: A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2008.10.018 – volume: 19 start-page: 943 year: 2019 ident: 10.1016/S0140-6736(20)30552-3_bib26 article-title: Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(19)30392-5 – volume: 305 start-page: 1124 year: 2004 ident: 10.1016/S0140-6736(20)30552-3_bib9 article-title: Intercontinental spread of pyrimethamine-resistant malaria publication-title: Science doi: 10.1126/science.1098876 – volume: 18 start-page: 913 year: 2018 ident: 10.1016/S0140-6736(20)30552-3_bib30 article-title: Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30297-4 – volume: 64 start-page: 12 issue: suppl 1–2 year: 2001 ident: 10.1016/S0140-6736(20)30552-3_bib10 article-title: The public health impact of chloroquine resistance in Africa publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2001.64.12 – volume: 62 start-page: e01068 year: 2018 ident: 10.1016/S0140-6736(20)30552-3_bib12 article-title: Investigating the efficacy of triple artemisinin-based combination therapies for treating Plasmodium falciparum malaria patients using mathematical modeling publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01068-18 – volume: 1 start-page: 37 year: 2009 ident: 10.1016/S0140-6736(20)30552-3_bib24 article-title: A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma publication-title: Bioanalysis doi: 10.4155/bio.09.6 – volume: 371 start-page: 411 year: 2014 ident: 10.1016/S0140-6736(20)30552-3_bib2 article-title: Spread of artemisinin resistance in Plasmodium falciparum malaria publication-title: N Engl J Med doi: 10.1056/NEJMoa1314981 – reference: 32240626 - Lancet. 2020 Apr 25;395(10233):1344. doi: 10.1016/S0140-6736(20)30738-8. – reference: 33341138 - Lancet. 2021 Dec 19;396(10267):1976. doi: 10.1016/S0140-6736(20)32400-4. – reference: 32171077 - Lancet. 2020 Apr 25;395(10233):1316-1317. doi: 10.1016/S0140-6736(20)30560-2. |
| SSID | ssj0004605 |
| Score | 2.6681666 |
| Snippet | Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination... Summary Background Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple... |
| SourceID | pubmedcentral proquest gale pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1345 |
| SubjectTerms | Adolescent Adult Amodiaquine Amodiaquine - administration & dosage Amodiaquine - therapeutic use Anthraquinones - administration & dosage Anthraquinones - therapeutic use Antimalarials - administration & dosage Antimalarials - therapeutic use Artemether Artemether, Lumefantrine Drug Combination - administration & dosage Artemether, Lumefantrine Drug Combination - therapeutic use Artemisinin Artemisinins - administration & dosage Artemisinins - therapeutic use Artesunate Charities Clinical trials Combination therapy Dihydroartemisinin Drug dosages Drug Resistance Drug Therapy, Combination Drugs EKG Electrocardiography Female Fever Health services Humans Laboratories Malaria Malaria, Falciparum - drug therapy Male Medical research Mefloquine Mefloquine - administration & dosage Mefloquine - therapeutic use Multidrug resistant organisms Oral administration Parasites Patients Plasmodium falciparum Plasmodium falciparum - drug effects Polymerase Chain Reaction Quinolines - administration & dosage Quinolines - therapeutic use Randomization Risk Treatment Outcome Vector-borne diseases Vomiting Young Adult |
| Title | Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673620305523 https://dx.doi.org/10.1016/S0140-6736(20)30552-3 https://www.ncbi.nlm.nih.gov/pubmed/32171078 https://www.proquest.com/docview/2424142474 https://www.proquest.com/docview/2377351713 https://pubmed.ncbi.nlm.nih.gov/PMC8204272 |
| Volume | 395 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaglRAXxJtAKUbiAFJNY8eOEy6oVK0qpFYVtNLeLMd2YKXdpOxufiF_jJm82kWF9rKKNp44yUxmvrHnQcg7pbVPQwhMZ7FjEpQky1RWsNK73OXeCV5ivvPxSXp0Lr9O1KRfcFv2YZWDTmwVta8drpHvYhoDZmVp-fniF8OuUbi72rfQuEs2OSARbN2gJ_q6vMg2xP0yg2f3-_jnexF_wLJXgiX_sk1_K-sr1mo9kvKKaTp8SB70mJLudULwiNwJ1WNy77jfNX9Cfp8tcDmdYvgmsBVbQjC0Xp7Co4Nn3DKHdplY4DhTjNRolrceDrCXgnUcYtNh3ClA8nntp82clnaGUdsLOJxb8KKn9hO1tA1jbJ8m7FBs4MVAGMNsh4Ll9DVMipP1OZu0bSzylJwfHpztH7G-eQNzKotXzHOd-eC4FzYpee5t7AGapKkqRVa4RDmdlt6C8-Rj7WTmZSocaAMLcMZaZcvkGdmo6iq8IDTNuStzyQFrOem1LZyyMi4y3HO0RWojIge2GddXNscGGzNzTQibiE3LbZNE5ONIdtGV9riJIB1kwgzvADStAeNzE2E2EvbApgMstyF9g8JnsFRHhbFAP2yzXBqzl4IvmSsAgxHZGuTS9PpnaS6_loi8HU8D-3A7yFahbmBMonWiuOYwyfNOjMf3kMDVOaDHiOg1AR8HYFXy9TPV9GdbnRwgpRRavPz_bb0i9wWuXMSSCbVFNlaLJrwGeLcqtttvGH6zfb5NNr8cnJx--wOIklBt |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkIAXxJ3CYEYCCaSZJY4dJ0gITcDUsXVCopP65jm2s1Vq09GLEH-KP8Ef45zctqLB9rK3qvGJW5_P52KfCyEvpVIu9t4zlQSWCRCSLJFJxnJnU5s6y8Mc8517-3H3QHwZyMEK-dXkwmBYZSMTS0HtJhbPyDcxjQGzspT4cPKdYdcovF1tWmhUsNj1P3-AyzZ7v_MJ-PuK8-3P_Y9dVncVYFYmwZy5UCXO29BxE-Vh6kzgQGfGscx5ktlIWhXnzoBV7wJlReJEzC3A1ICeNUaaPIL3XiPXBV4xwv5RA3VeHmYZUn-aMbT5rf3yNQ_eYJktzqJ_6cK_lcMZ7bgcuXlGFW7fIbdrG5ZuVaC7S1Z8cY_c6NW39PfJ7_4Uj-8phosCjLAFBUNt6SgsNXjiJRholfkFjjrFyJDF7NLDwcymoI2bWHgY9xVcgPHEDRdjmpsRRolP4ePYgNc-NO-ooWXYZPlv_AbFhmEMwO9HGxQ0tZvApDhZnSNKy0YmD8jBlbD1IVktJoV_TGichjZPRQi2nRVOmcxKI4IswTtOk8WmQ0TDNm3rSurY0GOkzwmZ44Euua2jDnnbkp1UpUQuIogbTOhmDUCya1B2FxEmLWFtSFUG0mVI1xF8GkuDFBh7dGQWs5nWWzH4rqkE47ND1hpc6lrezfTp7uyQF-1jYB9eP5nCTxYwJlIqkqEKYZJHFYzbdYjg7SFYqx2ilgDeDsAq6MtPiuFxWQ0dTFjBFX_y_5-1Tm52-709vbezv_uU3OJ4ahIIxuUaWZ1PF_4ZmJbz7Hm5nyk5vGoB8gfw9Ytt |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJk28IL4pDGYkkECa18Sx4wRpQoOt2hirKtikvRnHdqBSm45-CPH38cZfxV2aZCsabC97ixJf3ObO97uz74OQF1IpF3vvmUoCywQoSZbIJGO5s6lNneVhjvnOh91471h8OJEnS-R3nQuDYZW1TiwVtRtZ3CNvYxoDZmUp0c6rsIjeTuft6XeGHaTwpLVup2GqNgtuqyw3ViV5HPifP8Cdm2zt7wDvX3Le2T16v8eqjgPMyiSYMheqxHkbOm6iPEydCRzgaRzLnCeZjaRVce4MWPwuUFYkTsTcgggbwGBjpMkjeO8NsqIA9cERXHm32-19uihLswy4P8snan9ubr7iwWsswsVZ9C-k_Bs6zmHnYlznOaDs3Ca3KguXbs9F8g5Z8sVdsnpYneHfI7-Oxri5TzGYFIQMG1QwxFJHgRHgp5eiQud5YeDGU4wbmU2uPByMcApYXUfKw7geOAjDkevPhjQ3A4whH8Pl0IBP3zdvqKFlUGX5b_wGxXZiDJaGH2xQwHE3gklxsiqDlJZtTu6T42th7AOyXIwK_4jQOA1tnooQLD8rnDKZlUYEWYInoCaLTYuImm3aVnXWsd3HQF8QUMcDXXJbRy2y2ZCdzguNXEYQ1zKh628Ael8DFF5GmDSElZk1N5-uQrqOwqexcEiBS_CrmU0mWm_H4NmmEkzTFlmr5VJX2nCiz9ZuizxvHgP78HDKFH40gzGRUpEMVQiTPJyLcfMdInh7CLZsi6gFAW8GYI30xSdF_1tZKx0MXMEVf_z_n7VOVkGZ6I_73YMn5CbHLZVAMC7XyPJ0PPNPwe6cZs-qBU3Jl-vWIX8ApM-WSA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Triple+artemisinin-based+combination+therapies+versus+artemisinin-based+combination+therapies+for+uncomplicated+Plasmodium+falciparum+malaria%3A+a+multicentre%2C+open-label%2C+randomised+clinical+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Rob+W+van+der+Pluijm&rft.au=Tripura%2C+Rupam&rft.au=Hoglund%2C+Richard+M&rft.au=Aung+Pyae+Phyo&rft.date=2020-04-25&rft.pub=Elsevier+Limited&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=395&rft.issue=10233&rft.spage=1345&rft_id=info:doi/10.1016%2FS0140-6736%2820%2930552-3&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |